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INTRODUCTION: Osteoporosis is a common complication of chronic liver diseases. However, there is limited
information about autoimmune liver diseases as a factor of secondary osteoporosis. Therefore, we aimed to
investigate the autoantibodies of autoimmune liver diseases in patients with osteoporosis.
METHODS: One hundred fifty female patients with postmenopausal osteoporosis were included. Bone mineral
density was measured by dual energy X-ray absorptiometry. We analysized autoantibodies including antinuclear
antibodies, liver membrane antibodies, anti-liver/kidney microsomal autoantibodies1, liver-specific protein, anti-
smooth muscle antibodies, and anti-mitochondrial antibodies by indirect immunofluorescence. Serum was assayed
for the levels of aminotransferases.
RESULTS: The mean age of the patients was 63,13¡8,6 years. The mean values of L1-L4 T-scores and femur total
T-scores were -3,08¡0,58 and -1,53¡0,81, respectively. Among the 150 patients with osteoporosis, 14 (9.3%) were
antinuclear antibodies, four (2.7%) were liver membrane antibodies, three (2.0%) were anti-liver/kidney microsomal
autoantibodies1, and two (1.3%) were liver-specific protein positive. None of the patients had anti-mitochondrial
antibodies or smooth muscle antibodies positivity. The mean values of levels of aminotransferases were within
normal range.
CONCLUSIONS: The presence of liver membrane antibodies, liver-specific protein, and anti-liver/kidney microsomal
autoantibodies1 has permitted us to see that there may be some suspicious clues of autoimmune liver diseases in
patients with osteoporosis as a secondary risk factor. On the other hand, there is a need for comprehensive studies
with a larger sample size and studies designed to compare the results with a normal population to understand the
clinical importance of our findings.
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INTRODUCTION
Osteoporosis (OP) is usually defined as a skeletal disease
characterized by low bone mass and microarchitectural
deterioration of bone tissue, leading to enhanced bone
fragility and increase in fracture risk.1 It affects up to one in
two women and one in five men over the age of 50.2 It is a
worldwide disease seen in all racial groups and in both
males and females.3 In addition to being a common disease,
OP becomes a serious health issue due to the increase in
morbidity, mortality, and financial burden related with
osteoporotic fractures.4-6
Osteoporosis can be classified as primary and secondary
OP according to the underlying causes. Secondary OP may
be described as the low mineral density in which an
underlying cause or factor can be defined other than those
attributable to the postmenopausal state or aging.7 Primary
OP refers to OP when a secondary cause cannot be found.8
There are a number of secondary causes of osteoporosis
such as hypogonadism or hyperparathyroidism, which are
treatable, and renal failure, which should be considered
more seriously. Chronic liver diseases also play an
important role among secondary factors of OP.9,10
Bone disease is a major complication of chronic liver
disease. OP is more commonly seen in patients with liver
diseases as compared to the normal population, showing
variable prevalence according to the patient selection and
diagnostic criteria.11,12 OP is a common complication of
chronic liver diseases such as cholestatic disorders, alcoholic
liver diseases, posthepatitic cirrhosis, and autoimmune liver
diseases (ALD).13 Types of ALD are autoimmune hepatitis
(AH), primary biliary cirrhosis (PBC), and sclerosing
cholangitis. ALD affects women at any age with a wide
range of clinical presentations. In some cases, the disease is
incidentally diagnosed during routine laboratory tests,
while it shows a fulminate course in some others.14
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One of the main characteristics of the disease is the
presence of circulating autoantibodies. It has been sug-
gested that liver membrane antibodies (LMA) and liver
specific protein (LSP) are associated with ALD.15,16 Defined
antibodies are antinuclear antibodies (ANA), anti-smooth
muscle antibodies (SMA), and anti-liver/kidney microso-
mal autoantibodies1 (anti-LKM1) in addition to perinuclear
antineutrophil cytoplasmic antibodies (pANCA), antibodies
to liver-cytosol type 1 (anti-LC-1), autoantibodies to soluble
liver antigen/liver pancreas antigen (anti-SLA/LP), anti-
bodies to the asialoglycoprotein receptor (anti-ASGPR), and
anti-mitochondrial antibodies (AMA).14,17
The prevalence of OP is higher in patients with PBC, and
osteoporotic fractures are more prevalent in patients with
AH treated with glucocorticoids.18 However, it is not clear
whether or not chronic liver diseases – especially ALD – are
related to the secondary OP. There are a few studies
investigating liver diseases as a secondary cause of OP.8,19
Therefore, we aimed to assess the circulating autoantibodies
related to ALD in patients with OP.
MATERIALS AND METHODS
The study was conducted at Afyon Kocatepe University
Hospital following the approval of the Ethical Committee
for Medical Research of the university. Postmenopausal
women age 50 or older with OP were included in the study.
Two hundred and eighty-seven postmenopausal women
were evaluated. Bone mineral density (BMD) was measured
by dual energy X-ray absorptiometry (DXA, HOLOGIC Q
DR 4500 W) both at the lumbar spine (anteroposterior
projection of L1–L4), and the proximal femur (total score) if
the patients were 50 years or older. Osteoporosis is defined
as T score below -2.5 at any site according to WHO
guidelines.1 Smoking, alcohol use, medication (especially
drugs with high risk of liver toxicity), malignancy, history of
gastrointestinal system (thyroid gland, kidney, and liver
diseases), rheumatologic conditions, and nutrition were
questioned in detail. Patients with secondary risk factors
and anatomic deformity in lumbar and femoral region that
affects BMD were excluded. In total, 287 postmenopausal
women were evaluated; of these, 150 presented the criteria
for participation in this study.
Venous blood samples were drawn in the morning after an
overnight fast. Serum levels of aminotransferases (aspartate
aminotransferase-AST, alanine aminotransferase-ALT), cal-
cium (Ca), phosphate (PO4), alkaline phosphatase (ALP),
parathyroid hormone (PTH), 25-(OH) vitamin D, osteocalcin
(OC), and serum C-telopeptide cross-linked collagen type I
(CTX) were measured on the same day. Serum PTH was
measured by immunoradiometric assay (IRMA, USA).
Serum CTX was measured by electrochemiluminescence
immunoassay (ECLIA, Germany). Serum osteocalcin was
measured with an RIA (radioimmunoassay) technique
(DiaSorin, Saluggia, Italy). The level of 25-(OH) vitamin D
was measured by radioimmunoassay (RIA) (Nichols Institute
Diagnostics, USA). The levels of Ca, PO4, and ALP were
measured by colorimetric method. Serum was assayed using
an autoanalyzer to measure the levels of aminotransferases.
All blood tests were performed in a single laboratory using
reference ranges of this laboratory’s data.
Serum samples were analyzed for autoantibodies by
indirect immunofluorescence (IIF) on a substrate kit
(Euroimmun, Germany) that included fluorescein-conju-
gated goat antibodies to human immunoglobulin G (IgG).
IIF patterns were read at serum dilutions of 1:100 for ANA,
SMA, AMA, and anti-LKM1 positivity on a Zeiss Axioskop
(Carl Zeiss, Jena, Germany) by the same experienced
microbiologist. LMA and LSP were tested by the same
method with minimal titers for positivity being 1:80. The
levels of aminotransferases were re-examined when auto-
antibody positivity was determined.
The analyses were carried out using SPSS version 13.5.
Descriptive analysis was carried out and data were
expressed as percentages (%), means, and standard devia-
tions.
RESULTS
Two hundred and eighty-seven postmenopausal women
were evaluated and, of these, 150 patients were found to be
eligible to include in this study. The mean age of the
patients was 63,13¡8,6 years. The mean values of L1-L4
T-scores and femur total T-scores, were -3,08¡0,58 and
-1,53¡0,81, respectively. Upon evaluation of the question-
naires, none of the patients had signs or symptoms of liver
diseases.
The mean values of the enzymes reflecting liver functions
and markers of bone metabolism are shown in Table 1. The
mean values for all the laboratory tests were within the
normal range.
Among the 150 patients with OP, 14 (9.3%) were ANA,
four (2.7%) were LMA for 1:80 titers, three (2.0%) were anti-
LKM1, and two (1.3%) were LSP positive. None of the
patients had AMA or SMA positivity. Serological para-
meters are summarized in Table 2.
Only one patient was found to have positivity for two and
more autoantibodies (LMA and anti-LKM1). In laboratory
examination of the patient, all biochemical tests were within
the normal range.
Table 1 - Values of serum aminotransferases and bone
metabolism markers.
Serum Type
Mean
Values
Min-Max
Values
Normal
Values
Serum AST (U/l) 22.37¡17.08 2.55-66 0-32
Serum ALT (U/l) 20.10¡10.34 5.0-190.0 0-41
Serum ALP (U/l) 227.87¡69.96 42.9-387.2 98-278
Serum Ca (mg/dl) 9.87¡0.53 8.45-11.48 8.2-10.2
Serum PO4(mg/dl) 3.54¡0.54 2.1-4.75 2.7-4.5
Serum PTH (pg/ml) 49.84¡45.07 4.0-96.0 10-70
25-OH-vitamin D (ng/ml) 28.96¡36.58 12.3-74 10-50
Serum Osteocalcin (ng/ml) 11.77¡13.28 1.01-64.01 6.8-34
Serum CTX (ng/ml) 0.55¡0.38 0.33-1.96 0.33-0.78
Table 2 - Liver autoantibodies positivity (%) in patients
with osteoporosis
Positivity
Autoantibodies n (150) %
ANA 14 9.3
LMA 4 2.7
Anti-LKM1 3 2.0
LSP 2 1.3
SMA 0 0
AMA 0 0
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Two patients were found to have positive for both ANA
and higher ALT levels, whereas three patients had higher
ALT levels without autoantibodies positivity. AST and ALT
levels were within normal range in patients with the other
autoantibodies positivity.
DISCUSSION
In this study, we investigated the autoantibodies of ALD
in patients with OP. Among the 150 patients with OP, 14
(9.3%) were ANA, four (2.7%) were LMA, three (2.0%) were
anti-LKM1, and two (1.3%) were LSP positive. None of the
patients had AMA or SMA positivity. The levels of amino-
transferases of the patients with autoantibodies positivity
were within normal range.
Assessment of patients with OP is usually focused on the
measurement of bone mineral density and investigation of
bone metabolism markers. However, factors that affect the
bone structure are various, and some should be kept in
mind even if they have no place in routine laboratory
evaluation. Dimutrescu et al. denote that 32% to 37% of
women with low BMD have a history of other diseases or
medications known to contribute to OP.20 Among women
with OP, between 30% and 60% have a secondary cause.9
Liver diseases are one of the secondary causes investigated
in a limited number of studies. In one study, 272 patients
with OP, 96% of whom were women, were examined by
laboratory evaluation for liver diseases in addition to
endocrinologic disorders such as osteomalacia or hyperpar-
athyroidism and hematologic diseases such as anemia. They
mentioned that no unknown liver diseases were found in
their study cohort.19 Melton et al. investigated secondary
causes, including cirrhosis, in women and men with OP and
osteopenia. Cirrhosis was not found in study cases, but one
patient in the control group was found to have cirrhosis.21
Odabasi et al. found that three patients had chronic liver
diseases among 947 postmenopausal women with OP when
examined for secondary causes.8 Among the studies
mentioned above, ALD or definite autoantibodies of ALD
were not investigated. It is obvious that the diagnosis of
ALD is not totally dependent on the presence of auto-
antibodies; however, autoantibody positivity is the clue to
the disease. In the view of this, the present study is a rare
example of the studies investigating liver diseases in
patients with OP.
Among the 150 patients with OP, 14 (9.3%) were positive
for ANA at 1:100 titers. ANAs were the first autoantibodies
observed in AH and are still the most sensitive marker of
the disease. On the other hand, ANA positivity is not
specific for AH because positivity may occur in patients
with other diseases and even in healthy subjects.22,23 The
prevalence of ANA positivity is variable in the healthy
population. In spite of the variability, the prevalence is age
and sex dependant. Elderly over 60 years and females have
relatively high frequencies of ANA. It is estimated that 10%
to 15% of healthy people over the age of 65 are ANA
positive, and the titers are usually # 1:160.23,24 Consistent
with the literature, all our cohort were women, the mean age
of the patients was 63,13¡8,6 years, and 9.3% of the patients
were found ANA positivity for the 1:100 titers. Thereby, the
age and sex of the cohort may be the causes of the highest
prevalence of autoantibodies positivity for ANA. Tan et al.
describe that there is no cut-off value that can reliably
distinguish between normal and diseased populations.
However, it is considered that some healthy individuals
have low-titer ANA.23-25 In the present study, it is accepted
that 1:100 titers is enough for ANA positivity; the maximum
titers of ANA was not studied. Therefore, this cut-off value
was not enough to distinguish the pathologic value of ANA
positivity of the cohort. The abnormal levels of liver
function tests with ANA positivity may be useful for the
association with AH. Only two patients were positive for
ANA with ALT levels higher than upper limits. These
patients had no history for signs or symptoms of any liver
diseases. Therefore, clinical presentation of AH for the
patients was not considered.
Previous studies mention the diagnostic importance of
LSP and LMA in ALD.15,26,27 In our study population, four
(2.7%) patients were found to have positive for LMA and
two (1.3%) for LSP. The biochemical assessments of the
patients were within the normal range. The findings may be
coincidental, but AH should be considered for patients
when the elevated serum levels of aminotransferases are
determined during the follow-up period. LMA were also
found in some cases of alcoholic liver diseases,15 but one of
the exclusion criteria of the study was alcohol use.
Anti-LKM1 typically occurs in the absence of SMA and
ANA in patients with AH.28 In accordance with this data,
two patients were found to have with anti-LKM1 positivity
in the absence of SMA and ANA positivity. In Europe, anti-
LKM1 are found mainly in pediatric patients with AH and
are demonstrated in only 20% of adults with the disease.28
The result that 2% of women without history of liver disease
were found to positive for anti-LKM1 suggests that we
follow up the patients after a period of time.
The detection of AMA is nearly diagnostic of PBC, even in
the absence of symptoms. AMA positivity with normal liver
tests may be incidental and reflects a normal 0.5% incidence
in the general population.29,30 Among the patients of the
present study, AMA positivity was not detected. A possible
explanation for the apparent difference between the result
presented in this study and the number considered for the
normal population (0.5%) may be the sample size. SMA
facilitates diagnosis of AH and discriminates subtypes of
the disease.22 No patients were found to have SMA
positivity in the present study.
Jamal et al. investigated the clinical utility of laboratory
testing including serum aminotransferases to assess if an
underlying medical condition is contributing to bone loss.
They report that the prevalence of abnormal liver function
tests in women with OP compared to women without was
not different.31 Among the subjects included the present
study, the mean levels of AST and ALT were within the
normal range. Analyzing aminotransferases may be helpful
to determine the abnormal laboratory tests findings condi-
tional upon a diagnosis of liver diseases. On the other hand,
this analysis has not permitted us to obtain any additional
information because two patients were found to have
positive for both ANA and higher ALT levels, whereas
three patients had higher ALT levels without any auto-
antibodies positivity.
Our study has several limitations. First, the clinical
importance of our findings seems debatable. The clinical
importance can be discussed if it is possible to compare the
prevalence of autoantibodies detected in the study popula-
tion with the prevalence in age-matched postmenopausal
women without OP. Unfortunately, the number of volun-
teers without OP was not enough to constitute a control
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group for this study. In addition, there were no similar
studies to compare our findings. Notwithstanding, the
percentage of patients with positive autoantibodies may
be significant. On the other hand, these findings could also
attributed to normal variables or could be considered as
coincidental. Studies with larger sample sizes may help us
to elucidate the clinical importance of our findings. The
second limitation of the study is adapting our findings to
clinical practice. Our results may not be generalized, and
similar studies are required to determine whether labora-
tory testing should include autoantibodies as a marker of
secondary causes of OP. Finally, the sample size is relatively
small – the population of the study was derived from a
single academic center– whereas OP is a widespread
disease. Furthermore, our exclusion of subjects ineligible
to participate in the study may have caused a smaller
sample size than hoped.
CONCLUSIONS
This study assessed the presence of definite autoantibo-
dies related with ALD in patients with OP. Regardless of the
most frequently detected antibody-ANA in the present
study, the presence of LMA, LSP, and anti-LKM1 has
permitted us to see there may be some suspicious clues of
ALD in patients with OP as a secondary risk factor. On the
other hand, the clinical importance of the detected auto-
antibodies is unclear. There is a need for comprehensive
studies with a larger sample size and a design to compare
the results with normal population to understand if the
findings are normal variability or coincidental.
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